Heloisa Milioli

1.0k total citations
13 papers, 347 citations indexed

About

Heloisa Milioli is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Heloisa Milioli has authored 13 papers receiving a total of 347 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 5 papers in Molecular Biology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Heloisa Milioli's work include Cancer-related Molecular Pathways (4 papers), Advanced Breast Cancer Therapies (3 papers) and Estrogen and related hormone effects (2 papers). Heloisa Milioli is often cited by papers focused on Cancer-related Molecular Pathways (4 papers), Advanced Breast Cancer Therapies (3 papers) and Estrogen and related hormone effects (2 papers). Heloisa Milioli collaborates with scholars based in Australia, Brazil and Germany. Heloisa Milioli's co-authors include Pablo Moscato, Carlos Riveros, Inna Tishchenko, Regina Berretta, Elgene Lim, C. Elizabeth Caldon, Sarah Alexandrou, Rhiannon Coulson, Rubens Silveira de Lima and Davendra Segara and has published in prestigious journals such as PLoS ONE, Pharmacological Research and Breast Cancer Research.

In The Last Decade

Heloisa Milioli

12 papers receiving 344 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Heloisa Milioli Australia 12 198 131 113 75 36 13 347
Eunice Murage United States 9 255 1.3× 115 0.9× 79 0.7× 59 0.8× 12 0.3× 12 419
Nicole Willemsen‐Seegers Netherlands 11 229 1.2× 99 0.8× 46 0.4× 49 0.7× 13 0.4× 18 371
Ellen Karasik United States 11 207 1.0× 59 0.5× 59 0.5× 63 0.8× 30 0.8× 22 361
Yun‐Song Yang China 10 454 2.3× 194 1.5× 346 3.1× 133 1.8× 15 0.4× 14 709
Martine B.W. Prinsen Netherlands 11 270 1.4× 151 1.2× 65 0.6× 80 1.1× 15 0.4× 19 456
Antoon M. van Doornmalen Netherlands 10 196 1.0× 112 0.9× 41 0.4× 44 0.6× 9 0.3× 16 386
Yu‐Chen Pei China 9 300 1.5× 158 1.2× 228 2.0× 100 1.3× 30 0.8× 14 502
Peizhi Ma China 10 422 2.1× 45 0.3× 342 3.0× 129 1.7× 10 0.3× 21 571
Diana Melchers Netherlands 10 166 0.8× 71 0.5× 42 0.4× 80 1.1× 164 4.6× 20 372
Hengyu Li China 11 470 2.4× 96 0.7× 394 3.5× 43 0.6× 21 0.6× 17 631

Countries citing papers authored by Heloisa Milioli

Since Specialization
Citations

This map shows the geographic impact of Heloisa Milioli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heloisa Milioli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heloisa Milioli more than expected).

Fields of papers citing papers by Heloisa Milioli

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heloisa Milioli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heloisa Milioli. The network helps show where Heloisa Milioli may publish in the future.

Co-authorship network of co-authors of Heloisa Milioli

This figure shows the co-authorship network connecting the top 25 collaborators of Heloisa Milioli. A scholar is included among the top collaborators of Heloisa Milioli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heloisa Milioli. Heloisa Milioli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Alexandrou, Sarah, Christine S. Lee, Kristine J. Fernandez, et al.. (2025). JNK pathway suppression mediates insensitivity to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer. Journal of Experimental & Clinical Cancer Research. 44(1). 244–244.
2.
Milioli, Heloisa, et al.. (2023). Enhancing metabolite coverage in MALDI-MSI using laser post-ionisation (MALDI-2). Analytical Methods. 15(34). 4311–4320. 19 indexed citations
3.
Milioli, Heloisa, Suraya Roslan, Patric J. Jansson, et al.. (2023). Innovative thiosemicarbazones that induce multi-modal mechanisms to down-regulate estrogen-, progesterone-, androgen- and prolactin-receptors in breast cancer. Pharmacological Research. 193. 106806–106806. 15 indexed citations
4.
Milioli, Heloisa, Sarah Alexandrou, Elgene Lim, & C. Elizabeth Caldon. (2020). Cyclin E1 and cyclin E2 in ER+ breast cancer: prospects as biomarkers and therapeutic targets. Endocrine Related Cancer. 27(5). R93–R112. 25 indexed citations
5.
Portman, Neil, Heloisa Milioli, Sarah Alexandrou, et al.. (2020). MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer. Breast Cancer Research. 22(1). 87–87. 49 indexed citations
6.
Heng, Benjamin, Ayse Bilgin, David B. Lovejoy, et al.. (2020). Differential kynurenine pathway metabolism in highly metastatic aggressive breast cancer subtypes: beyond IDO1-induced immunosuppression. Breast Cancer Research. 22(1). 113–113. 47 indexed citations
7.
Chia, Kee Ming, Heloisa Milioli, Neil Portman, et al.. (2018). Non-canonical AR activity facilitates endocrine resistance in breast cancer. Endocrine Related Cancer. 26(2). 251–264. 28 indexed citations
8.
Milioli, Heloisa, Inna Tishchenko, Carlos Riveros, Regina Berretta, & Pablo Moscato. (2017). Basal-like breast cancer: molecular profiles, clinical features and survival outcomes. BMC Medical Genomics. 10(1). 19–19. 73 indexed citations
9.
Milioli, Heloisa, Guy Costa, Cícero Úrban, et al.. (2016). Comparative proteomic analysis of ductal and lobular invasive breast carcinoma. Genetics and Molecular Research. 15(2). 15 indexed citations
10.
Milioli, Heloisa, et al.. (2016). Iteratively refining breast cancer intrinsic subtypes in the METABRIC dataset. BioData Mining. 9(1). 2–2. 15 indexed citations
11.
Tishchenko, Inna, Heloisa Milioli, Carlos Riveros, & Pablo Moscato. (2016). Extensive Transcriptomic and Genomic Analysis Provides New Insights about Luminal Breast Cancers. PLoS ONE. 11(6). e0158259–e0158259. 17 indexed citations
12.
Milioli, Heloisa, et al.. (2015). The Discovery of Novel Biomarkers Improves Breast Cancer Intrinsic Subtype Prediction and Reconciles the Labels in the METABRIC Data Set. PLoS ONE. 10(7). e0129711–e0129711. 19 indexed citations
13.
Milioli, Heloisa, et al.. (2015). Comparative proteomics of primary breast carcinomas and lymph node metastases outlining markers of tumor invasion.. PubMed. 12(2). 89–101. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eunice Murage Breakdown of academic impact, for papers by Nicole Willemsen‐Seegers Breakdown of academic impact, for papers by Ellen Karasik Breakdown of academic impact, for papers by Yun‐Song Yang Breakdown of academic impact, for papers by Martine B.W. Prinsen Breakdown of academic impact, for papers by Antoon M. van Doornmalen Breakdown of academic impact, for papers by Yu‐Chen Pei Breakdown of academic impact, for papers by Peizhi Ma Breakdown of academic impact, for papers by Diana Melchers Breakdown of academic impact, for papers by Hengyu Li
Rankless by CCL
2026